In 2016 we made, through our partnership with Sparks, the
“Mechanisms of often fatal primary infection with the
human tumor virus Epstein Barr virus”.
Professor Christian Münz and Dr. Lynn Wong, University of
Zürich, Switzerland. £50,000 over two years.
Mutations in X chromosome-linked inhibitor of apoptosis
protein (XIAP) have been found in patients with X-linked lymphoproliferative
disease (XLP2). These reduce the levels of XIAP and presumably compromise
Epstein Barr virus (EBV) specific immune control during primary infection,
leading to often fatal lymphoproliferative disease during primary EBV infection
of XLP2 patients.
How this research will help
The proposed research project is designed to understand how
XIAP inhibition compromises EBV specific immune control and tumorigenesis in
the only small animal in vivo model of this infection.
This knowledge should indicate which immune compartments
have to be therapeutically strengthened or even adoptively transferred into
XLP2 patients in order for them to survive primary EBV infection.
Help little Cavan beat a rare blood condition
The Northern Ireland grandfather of a six year old boy fighting a rare blood